Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Felipe Ortiz

Pulmonary Disease Leesburg, FL Medical Doctor

NPI 1811989569 CMS profile 263703

501 Medical Plaza Dr, Suite 102, Leesburg, FL 34748

Open in the dashboard

General payments

$17,025

798 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Felipe Ortiz of Leesburg, FL is reported in the CMS Open Payments database as having received $17,025 across 798 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,920 150
2024 General $3,357 136
2023 General $2,426 108
2022 General $1,991 97
2021 General $1,921 107
2020 General $1,461 75
2019 General $1,949 125

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Felipe Ortiz
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Felipe Ortiz were reported at $3,920. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Felipe Ortiz Pulmonary Disease median Middle half National median
2019 $1,949 $377 $109–$1,340 $163
2020 $1,461 $230 $56–$907 $114
2021 $1,921 $269 $68–$1,072 $132
2022 $1,991 $390 $100–$1,457 $149
2023 $2,426 $419 $114–$1,659 $160
2024 $3,357 $476 $123–$1,818 $164
2025 $3,920 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $2,586 145 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $2,209 101 payments
  3. AstraZeneca Pharmaceuticals LP $1,668 71 payments
  4. Actelion Pharmaceuticals US, Inc. $1,522 56 payments
  5. Regeneron Healthcare Solutions, Inc. $907 28 payments
  6. United Therapeutics Corporation $683 18 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $631 22 payments
  8. Grifols USA, LLC $570 34 payments
  9. Genzyme Corporation $559 22 payments
  10. Insmed, Inc. $531 24 payments
  11. Other $5,159 277 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $16,513 787 payments
  2. Education $512 11 payments
Products named General payments · program years 2019–2025
  1. UPTRAVI $1,352 49 payments
  2. TRELEGY ELLIPTA $1,186 68 payments
  3. FASENRA $862 32 payments
  4. OFEV $849 38 payments
  5. NUCALA $803 39 payments
  6. OPSUMIT $760 27 payments
  7. GLASSIA $758 29 payments
  8. DUPIXENT Immunology $599 24 payments
  9. Prolastin-C Liquid $570 34 payments
  10. DUPIXENT Inflammation And Immunology $535 18 payments
  11. Other $10,545 509 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 48 drugs

Part D claims

2,418

Median for Pulmonary Disease: 936

Drug cost

$1,746,426

Median for Pulmonary Disease: $487,987

Branded share of claims

61.2%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ofev Nintedanib Esylate Brand 39 $502,634
Opsumit Macitentan Brand 21 $265,474
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 200 $248,662
Breo Ellipta Fluticasone/Vilanterol Brand 192 $136,189
Prolastin C Alpha-1-Proteinase Inhibitor Brand 13 $121,473
Nucala Mepolizumab Brand 30 $111,631
Spiriva Respimat Tiotropium Bromide Brand 102 $82,206
Arnuity Ellipta Fluticasone Furoate Brand 116 $51,222
Eliquis Apixaban Brand 30 $36,988
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 46 $33,343

The 10 drugs with the highest cost, of 48 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 32 billing codes

Paid by Medicare

$524,847

Medicare's payments for the services billed

Medicare patients

1,626

Average age 78

Services billed

6,303

849 women, 777 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 60%
Arthritis 59%
COPD 58%
Chronic kidney disease 47%
Heart failure 40%
Atrial fibrillation 40%
Diabetes 37%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
$422 — —
TRELEGY ELLIPTA
$228 200 —
OFEV
$217 39 —
TYVASO
$212 — —
ACTHAR
$191 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

798 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record